These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 34206855)

  • 1. Multiphoton Imaging of Ca
    Borile G; Zaglia T; E Lehnart S; Mongillo M
    J Clin Med; 2021 Jun; 10(13):. PubMed ID: 34206855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CaMKII inhibition has dual effects on spontaneous Ca
    Sadredini M; Haugsten Hansen M; Frisk M; Louch WE; Lehnart SE; Sjaastad I; Stokke MK
    Am J Physiol Heart Circ Physiol; 2021 Aug; 321(2):H446-H460. PubMed ID: 34270372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of RyR2 inhibitor EL20 in induced pluripotent stem cell-derived cardiomyocytes from a patient with catecholaminergic polymorphic ventricular tachycardia.
    Word TA; Quick AP; Miyake CY; Shak MK; Pan X; Kim JJ; Allen HD; Sibrian-Vazquez M; Strongin RM; Landstrom AP; Wehrens XHT
    J Cell Mol Med; 2021 Jun; 25(13):6115-24. PubMed ID: 34110090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arrhythmogenesis in a catecholaminergic polymorphic ventricular tachycardia mutation that depresses ryanodine receptor function.
    Zhao YT; Valdivia CR; Gurrola GB; Powers PP; Willis BC; Moss RL; Jalife J; Valdivia HH
    Proc Natl Acad Sci U S A; 2015 Mar; 112(13):E1669-77. PubMed ID: 25775566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Z16b, a natural compound from Ganoderma cochlear is a novel RyR2 stabilizer preventing catecholaminergic polymorphic ventricular tachycardia.
    Wan JF; Wang G; Qin FY; Huang DL; Wang Y; Su AL; Zhang HP; Liu Y; Zeng SY; Wei CL; Cheng YX; Liu J
    Acta Pharmacol Sin; 2022 Sep; 43(9):2340-2350. PubMed ID: 35190699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of ryanodine receptor function prolongs Ca2+ release refractoriness and promotes cardiac alternans in intact hearts.
    Zhong X; Sun B; Vallmitjana A; Mi T; Guo W; Ni M; Wang R; Guo A; Duff HJ; Gillis AM; Song LS; Hove-Madsen L; Benitez R; Chen SR
    Biochem J; 2016 Nov; 473(21):3951-3964. PubMed ID: 27582498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting intracellular calcium cycling in catecholaminergic polymorphic ventricular tachycardia: a theoretical investigation.
    Sung RJ; Lo CP; Hsiao PY; Tien HC
    Am J Physiol Heart Circ Physiol; 2011 Oct; 301(4):H1625-38. PubMed ID: 21742998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogenic mechanism of a catecholaminergic polymorphic ventricular tachycardia causing-mutation in cardiac calcium release channel RyR2.
    Xiong J; Liu X; Gong Y; Zhang P; Qiang S; Zhao Q; Guo R; Qian Y; Wang L; Zhu L; Wang R; Hao Z; Wen H; Zhang J; Tang K; Zang WF; Yuchi Z; Chen H; Chen SRW; Zheng W; Wang SQ; Xu YW; Liu Z
    J Mol Cell Cardiol; 2018 Apr; 117():26-35. PubMed ID: 29477366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Catecholaminergic polymorphic ventricular tachycardia is caused by mutation-linked defective conformational regulation of the ryanodine receptor.
    Uchinoumi H; Yano M; Suetomi T; Ono M; Xu X; Tateishi H; Oda T; Okuda S; Doi M; Kobayashi S; Yamamoto T; Ikeda Y; Ohkusa T; Ikemoto N; Matsuzaki M
    Circ Res; 2010 Apr; 106(8):1413-24. PubMed ID: 20224043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EL20, a potent antiarrhythmic compound, selectively inhibits calmodulin-deficient ryanodine receptor type 2.
    Klipp RC; Li N; Wang Q; Word TA; Sibrian-Vazquez M; Strongin RM; Wehrens XHT; Abramson JJ
    Heart Rhythm; 2018 Apr; 15(4):578-586. PubMed ID: 29248564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Purkinje cells from RyR2 mutant mice are highly arrhythmogenic but responsive to targeted therapy.
    Kang G; Giovannone SF; Liu N; Liu FY; Zhang J; Priori SG; Fishman GI
    Circ Res; 2010 Aug; 107(4):512-9. PubMed ID: 20595652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calsequestrin 2 (CASQ2) mutations increase expression of calreticulin and ryanodine receptors, causing catecholaminergic polymorphic ventricular tachycardia.
    Song L; Alcalai R; Arad M; Wolf CM; Toka O; Conner DA; Berul CI; Eldar M; Seidman CE; Seidman JG
    J Clin Invest; 2007 Jul; 117(7):1814-23. PubMed ID: 17607358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutant ryanodine receptors in catecholaminergic polymorphic ventricular tachycardia generate delayed afterdepolarizations due to increased propensity to Ca2+ waves.
    Paavola J; Viitasalo M; Laitinen-Forsblom PJ; Pasternack M; Swan H; Tikkanen I; Toivonen L; Kontula K; Laine M
    Eur Heart J; 2007 May; 28(9):1135-42. PubMed ID: 17347175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of catecholaminergic polymorphic ventricular tachycardia in mice using novel RyR2-modifying drugs.
    Li N; Wang Q; Sibrian-Vazquez M; Klipp RC; Reynolds JO; Word TA; Scott L; Salama G; Strongin RM; Abramson JJ; Wehrens XHT
    Int J Cardiol; 2017 Jan; 227():668-673. PubMed ID: 27838126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phospholamban ablation rescues the enhanced propensity to arrhythmias of mice with CaMKII-constitutive phosphorylation of RyR2 at site S2814.
    Mazzocchi G; Sommese L; Palomeque J; Felice JI; Di Carlo MN; Fainstein D; Gonzalez P; Contreras P; Skapura D; McCauley MD; Lascano EC; Negroni JA; Kranias EG; Wehrens XH; Valverde CA; Mattiazzi A
    J Physiol; 2016 Jun; 594(11):3005-30. PubMed ID: 26695843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sarcoplasmic reticulum calcium leak contributes to arrhythmia but not to heart failure progression.
    Mohamed BA; Hartmann N; Tirilomis P; Sekeres K; Li W; Neef S; Richter C; Zeisberg EM; Kattner L; Didié M; Guan K; Schmitto JD; Lehnart SE; Luther S; Voigt N; Seidler T; Sossalla S; Hasenfuss G; Toischer K
    Sci Transl Med; 2018 Sep; 10(458):. PubMed ID: 30209242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arrhythmia initiation in catecholaminergic polymorphic ventricular tachycardia type 1 depends on both heart rate and sympathetic stimulation.
    Danielsen TK; Manotheepan R; Sadredini M; Leren IS; Edwards AG; Vincent KP; Lehnart SE; Sejersted OM; Sjaastad I; Haugaa KH; Stokke MK
    PLoS One; 2018; 13(11):e0207100. PubMed ID: 30399185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Slowed depolarization and irregular repolarization in catecholaminergic polymorphic ventricular tachycardia: a study from cellular Ca2+ transients and action potentials to clinical monophasic action potentials and electrocardiography.
    Paavola J; Väänänen H; Larsson K; Penttinen K; Toivonen L; Kontula K; Laine M; Aalto-Setälä K; Swan H; Viitasalo M
    Europace; 2016 Oct; 18(10):1599-1607. PubMed ID: 26705554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular basis of catecholaminergic polymorphic ventricular tachycardia.
    Györke S
    Heart Rhythm; 2009 Jan; 6(1):123-9. PubMed ID: 19121813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The RyR2-R2474S Mutation Sensitizes Cardiomyocytes and Hearts to Catecholaminergic Stress-Induced Oxidation of the Mitochondrial Glutathione Pool.
    Wegener JW; Wagdi A; Wagner E; Katschinski DM; Hasenfuss G; Bruegmann T; Lehnart SE
    Front Physiol; 2021; 12():777770. PubMed ID: 34955889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.